% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{AlfonsoPrieto:1024689,
      author       = {Alfonso-Prieto, Mercedes and Müller, Nicolas and Sergeeva,
                      Olga A. and Navarini, Luciano and Carloni, Paolo},
      title        = {{M}olecular insights into the neuroprotective effects of
                      chlorogenic acids mediated by the peroxisome
                      proliferator-activated receptor {PPAR}alpha},
      issn         = {0006-3495},
      reportid     = {FZJ-2024-02362},
      year         = {2024},
      abstract     = {The peroxisome proliferator-activated receptor PPARalpha
                      has been associated to neuroprotection against Parkinson’s
                      and Alzheimer’s diseases [1]. PPARalpha binds a wide
                      variety of ligands [2], including FDA-approved drugs,
                      suggesting that PPARalpha could be used as an alternative
                      therapeutic target against neurodegeneration. Endogenous
                      ligands of PPARalpha include fatty acids (such as oleic
                      acid, whose concentration is pathologically increased in
                      several neurodegenerative diseases) and their derivatives
                      (such as OLHA, the conjugate of oleic acid and histamine)
                      [3]. In addition, PPARalpha exogenous ligands span from
                      drugs against diabetes and hyperlipidemia to food molecules,
                      such as cinnamic acid [4-5] and the closely related
                      chlorogenic acids (CGAs). Using molecular simulations, we
                      have investigated the binding determinants of CGA-related
                      compounds. Our computational results, in combination with
                      experiments on brain slices, show that these novel PPARalpha
                      ligands could bind to the receptor similarly to known
                      endogenous agonists and drugs. In the long term, this
                      molecular information may be used as a stepping stone for
                      designing PPARalpha-based neuroprotective therapies.[1]
                      Willems S. et al. (2021) J. Med. Chem. 64:9592–9638.[2]
                      Kamata S. et al. (2020) iScience 23:101727.[3] Sergeeva O.A.
                      (2022) Neuropharmacology 215:109167.[4] Chandra S. et al.
                      (2019) Neurobiol. Dis. 124:379–395.[5] Prorok T. et al.
                      (2019) Neurochem. Res. 44(4):751–762.},
      month         = {Feb},
      date          = {2024-02-10},
      organization  = {Biophysical Society Meeting,
                       Philadelphia (USA), 10 Feb 2024 - 14
                       Feb 2024},
      subtyp        = {After Call},
      cin          = {IAS-5 / INM-9},
      ddc          = {570},
      cid          = {I:(DE-Juel1)IAS-5-20120330 / I:(DE-Juel1)INM-9-20140121},
      pnm          = {5241 - Molecular Information Processing in Cellular Systems
                      (POF4-524) / 5252 - Brain Dysfunction and Plasticity
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5241 / G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)24},
      url          = {https://juser.fz-juelich.de/record/1024689},
}